Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model
- PMID: 17478722
- DOI: 10.1126/science.1141736
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model
Abstract
Many potential treatments for Alzheimer's disease target amyloid-beta peptides (Abeta), which are widely presumed to cause the disease. The microtubule-associated protein tau is also involved in the disease, but it is unclear whether treatments aimed at tau could block Abeta-induced cognitive impairments. Here, we found that reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Abeta levels. Tau reduction also protected both transgenic and nontransgenic mice against excitotoxicity. Thus, tau reduction can block Abeta- and excitotoxin-induced neuronal dysfunction and may represent an effective strategy for treating Alzheimer's disease and related conditions.
Similar articles
-
Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in Mice.PLoS One. 2016 Jul 26;11(7):e0159435. doi: 10.1371/journal.pone.0159435. eCollection 2016. PLoS One. 2016. PMID: 27459671 Free PMC article.
-
Tau passive immunization inhibits not only tau but also Aβ pathology.Alzheimers Res Ther. 2017 Jan 10;9(1):1. doi: 10.1186/s13195-016-0227-5. Alzheimers Res Ther. 2017. PMID: 28073379 Free PMC article.
-
Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.J Neurosci. 2016 Sep 14;36(37):9647-58. doi: 10.1523/JNEUROSCI.1899-16.2016. J Neurosci. 2016. PMID: 27629715 Free PMC article.
-
Mouse models of Alzheimer's disease: the long and filamentous road.Neurol Res. 2003 Sep;25(6):590-600. doi: 10.1179/016164103101202020. Neurol Res. 2003. PMID: 14503012 Review.
-
Genetically modified mice models for Alzheimer's disease.Curr Top Med Chem. 2006;6(6):609-27. doi: 10.2174/156802606776743020. Curr Top Med Chem. 2006. PMID: 16712495 Review.
Cited by
-
Alzheimer's disease induced neurons bearing PSEN1 mutations exhibit reduced excitability.Front Cell Neurosci. 2024 Oct 9;18:1406970. doi: 10.3389/fncel.2024.1406970. eCollection 2024. Front Cell Neurosci. 2024. PMID: 39444394 Free PMC article.
-
The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease.Aging Dis. 2015 Mar 10;6(2):131-48. doi: 10.14336/AD.2014.0423. eCollection 2015 Mar. Aging Dis. 2015. PMID: 25821641 Free PMC article. Review.
-
Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.Exp Neurol. 2013 Aug;246:44-53. doi: 10.1016/j.expneurol.2012.06.003. Epub 2012 Jun 19. Exp Neurol. 2013. PMID: 22721767 Free PMC article. Review.
-
Modeling the complex pathology of Alzheimer's disease in Drosophila.Exp Neurol. 2015 Dec;274(Pt A):58-71. doi: 10.1016/j.expneurol.2015.05.013. Epub 2015 May 27. Exp Neurol. 2015. PMID: 26024860 Free PMC article. Review.
-
Immunotherapy Applied to Neuropsychiatric Disorders: a New Perspective of Treatment.J Mol Neurosci. 2015 Sep;57(1):139-41. doi: 10.1007/s12031-015-0587-5. Epub 2015 May 31. J Mol Neurosci. 2015. PMID: 26026601 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases